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ABSTRACT
Background: Information on neurocognitive outcome
following treatment of benign meningiomas is virtually
lacking. This is remarkable considering that survival in
these patients is the most favourable of all intracranial
tumours. The aim of the present study was therefore to
document the extent and nature of neurocognitive deficits
in patients with World Health Organization (WHO) grade I
meningioma after treatment.
Methods: 89 patients with WHO grade I meningioma
who underwent surgery with or without adjuvant radio-
therapy were individually matched to 89 healthy controls
for age, sex and educational level. Neurocognitive
functioning of patients was assessed at least 1 year
following treatment and compared with that of healthy
controls using the Student’s t test. Additionally, associa-
tions between tumour characteristics (size, lateralisation
and localisation), treatment characteristics (radiotherapy)
and epilepsy burden (based on seizure frequency and
antiepileptic drug use) and neurocognitive functioning
were investigated.
Results: Compared with healthy controls, patients with
meningioma showed significant impairments in executive
functioning (p,0.001), verbal memory (p,0.001),
information processing capacity (p = 0.001), psycho-
motor speed (p = 0.001) and working memory
(p = 0.006). Patients with skull base meningiomas
performed significantly lower on three out of six
neurocognitive domains compared with convexity menin-
giomas. Left-sided as opposed to right-sided meningio-
mas were related to verbal memory deficits. A higher
epilepsy burden was significantly associated with lower
executive functioning which primarily could be attributed
to antiepileptic drug use. No significant associations were
established between neurocognitive status and radio-
therapy or tumour volume.
Conclusions: Meningioma patients are characterised by
long term deficits in neurocognitive functioning that can
partly be attributed to the use of antiepileptic drugs and
tumour location but not to the use of radiotherapy.
Meningiomas are primary brain tumours that arise
from the meningeal coverings of the brain. With an
annual incidence of 6 per 100 000 population, they
account for 13–26% of all primary intracranial
tumours.1 2 Ninety per cent of the meningiomas
are benign World Health Organization (WHO)
grade I tumours.2 Patients commonly present with
epileptic seizures or focal neurological deficits
related to local brain or cranial nerve compression,
ranging from visual disturbances or hearing loss to
extremity weakness.3 4
Initial treatment consists of surgical resection.
Radiotherapyyieldsafavourableprognosis,specifically
for WHO grade II and III tumours revealing atypia
or anaplasia, and also reduces the risk of local
recurrence of grade I tumours after subtotal
resection. However, the clinical value and optimal
timing of radiotherapy after (in)complete surgery
or recurrence of WHO grade I meningiomas remain
subject to debate.5–8
Although radiotherapy is thought to signifi-
cantly contribute to long term neurocognitive
deficits in meningioma patients,9–11 it is unclear to
what extent these deficits are caused, in addition
to the tumour itself, by surgery or by other
treatment related factors. In patients with low
grade gliomas the use of antiepileptic drugs (AED)
was found to be associated with significantly
reduced neurocognitive functioning.12 For other
types of primary brain tumours it is known that
neurocognitive deficits can be attributed to a
combination of tumour and medical treatment
related factors.13
The primary aim of this study was to determine
the extent and nature of neurocognitive deficits of
patients with WHO grade I meningiomas.
Secondly, we examined the effects of tumour
characteristics (size, lateralisation and localisation),
treatment characteristics (surgery, radiotherapy)
and epilepsy burden (based on seizure frequency
and AED use) on neurocognitive functioning in
patients with meningioma after treatment.
Detailed information on the effect of available
treatment options on the frequency and severity of
neurocognitive deficits in meningioma patients
will offer support in the choice and timing of
treatment.
METHODS
Patients and healthy controls
In this multicentre cross sectional study, we
assessed all consecutive adult patients with WHO
grade I meningioma between 1999 and 2005
without clinical or radiological signs of tumour
recurrence for at least 1 year after treatment.
Patients had to be treated with surgery, with or
without adjuvant conventional external beam
conformal radiotherapy. They were recruited from
the VU University Medical Centre and the
Academic Medical Centre, Amsterdam, The
Netherlands. The medical ethics committee of
both centres approved the study protocol.
Eligibility of patients was checked with the
general practitioner and by patient chart review.
Excluded from the study were patients with
atypical or malignant meningioma (WHO grade
II or III) or who had one of the following
medical conditions that may interfere with normal
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neurocognitive functioning: tumours elsewhere in the CNS,
cerebrovascular pathology, congenital CNS malformations,
multiple sclerosis, Parkinson’s disease, organic psychosis,
dementia or schizophrenia. Also, patients had to have sufficient
proficiency of the Dutch language to be able to carry out the
neurocognitive tests.
Healthy controls providing normative data for the neurocog-
nitive tests were selected from the Maastricht Aging Study14
which is a large cross sectional study on the biomedical and
psychological determinants of cognitive aging of 2000 healthy
individuals aged 24–81 years. Patients and healthy controls were
individually matched with respect to sex, age and educational
level. Educational level was assessed by a Dutch scoring system15
consisting of an 8 point scale, ranging from unfinished primary
education (level 1) to university level (level 8).
The treating physician invited the patients by letter to
participate in the study. If patients agreed to participate, an
appointment was made for a neurocognitive assessment. Prior
to formal testing, patients completed a questionnaire concern-
ing sociodemographic data and health related quality of life16
(these data will be addressed in a separate paper).
Clinical data obtained at study entry included tumour
characteristics (histology, lateralisation, volume) and treatment
history (radiotherapy total dose and fraction dose, epilepsy and
AED use). All clinical data were derived from the medical
records.
Study measures
Neurological functioning and performance status
Neurological functioning was scored with the Neurological
Functioning Scale developed by Order and colleagues.17 Scores
range from 1 to 4, with higher scores indicating better
neurological functioning. Performance status was assessed by
means of the Karnofsky Performance Status scale (KPS).18 The
KPS is an overall indicator of the patient’s level of physical
functioning used frequently in clinical research in oncology. KPS
scores range from 0 (lowest level) to 100 (highest level). The
capacity to carry out activities of daily living was assessed by
means of the Barthel Activities of Daily Living Index19 consisting
of 10 items assessing continence of the bowels and bladder,
grooming, toilet use, feeding, transfer, mobility, dressing,
climbing stairs and bathing. Higher scores indicate higher levels
of functional independence (range 10–20). An inventory of brain
tumour related health problems was made with the Brain
Cancer Module (BCM20).20 The BCM20 is a questionnaire
containing 20 items grouped into four scales (future uncer-
tainty, visual disorder, communication deficit and motor
dysfunction) and seven single items (headache, seizure, drowsi-
ness, hair loss, itching, weakness of both legs and difficulty
controlling bladder function).
Neurocognitive functioning
Because the origin and severity of neurocognitive impairments
in meningioma patients might vary greatly, a wide range of
neurocognitive functions were assessed by means of a standard-
ised test battery (see table 1).21–24 Trained psychometricians,
supervised by a board certified neuropsychologist (MK),
administered the standardised neurocognitive test battery either
at home or at the hospital.
To accomplish data reduction, individual neurocognitive test
scores were converted into z scores using the means and SDs of
the matched healthy controls as a reference. Subsequently, z
scores were transformed into the following six neurocognitive
domains: (1) information processing capacity, (2) psychomotor
speed, (3) attentional functioning, (4) verbal memory, (5)
working memory and (6) executive functioning. Construction
of these neurocognitive domains was based on a principal
component analysis using Varimax rotation with Kaiser
normalisation performed on the z scores of healthy controls.12
The outcome of the principal component analysis was
confirmation of the neurocognitive domains conventionally
used in neuropsychological practice.
Because of the variety in seizure history and AED use,
patients were assigned to one of six levels on a single ordinal
scale, with higher levels representing a higher epilepsy burden:
level 1, epilepsy free; level 2, epilepsy, seizure free in the year
before testing without AEDs; level 3, epilepsy, seizure free in the
previous year with AED monotherapy; level 4, epilepsy, seizure
free in the previous year with AED polytherapy; level 5,
epilepsy, less than six seizures in the previous year and on AED
monotherapy or polytherapy; and level 6, epilepsy, more than
six seizures in the previous year with AED monotherapy or
polytherapy.12 Preoperative CT and/or MRI tumour volume was
calculated using the equation: 4/3p6 (Kx 6Ky 6Kz).
Statistical analysis
Using SPSS 11.0, Student two tailed t tests for independent
samples were employed to test for differences in neurocognitive
functioning between patients and controls. Associations
between brain tumour related health problems (BCM20),
radiotherapy (yes/no), epilepsy burden (level 1–6) and tumour
volume on the one hand and neurocognitive domain test scores
on the other, were explored by correlational and multiple
regression analyses. Student t tests were performed to
determine associations between neurocognitive functioning
and tumour lateralisation and localisation. Where relevant,
corrections for age, educational level and sex were made.
Statistical significance was set at p,0.05.
RESULTS
Sociodemographic and clinical characteristics
Of the 123 patients who met the inclusion criteria, 34 patients
were excluded; 16 patients could not be traced and 14 patients
declined participation as they expected testing to be too
burdensome. Three patients had insufficient proficiency of the
Dutch language and one patient had severely impaired hearing.
Thus 89 eligible patients remained to be studied.
Table 1 Neuropsychological tests used for assessment of
neurocognitive functioning
Test name Description
Letter–Digit Modalities Test21 Measures psychomotor speed that is relatively
unaffected by a decline in intellectual ability
Rey’s Auditory Verbal Learning Test22 Examines verbal learning capacity and
consolidation of verbal information into long
term memory
Working Memory Test22 Measures the speed of memory retrieval
processes
Digit Span23 Measures short term memory and working
memory
Category Verbal Fluency Test22 A measure of executive functioning and
semantic memory
Stroop Color Word Test22 Examines information processing speed,
selective attention and mental control
Concept Shifting Test24 Measures attention, visual searching, mental
processing speed and the ability to mentally
control simultaneous stimulus patterns
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As a consequence of the matching procedure, patients and
healthy controls did not differ significantly in age, sex or
educational level (table 2). The average time since treatment at
the moment of neuropsychological testing was 3.4 years. All 89
patients were treated with surgery; complete tumour resection
was achieved in 49 and incomplete resection in 40 patients.
Twenty-two patients received adjuvant conformal radiotherapy
with fraction doses of 1.8–2.0 Gc, with total doses ranging from
50 to 54 Gc. Irradiated patients had meningiomas of the skull
base (n = 12), tentorium (n = 3), convexity (n = 2), n opticus
(n = 1) or at both skull base and tentorium or convexity (n = 4).
Thirty patients had epileptic seizures prior to surgery. Of these,
22 patients became seizure free following surgery with (n = 12)
or without (n = 10) AEDs, seven patients reported no change in
epilepsy burden after surgery despite AEDs and four patients
reported worsening or onset of seizures postoperatively. At the
moment of neuropsychological testing, 23 patients were using
AEDs.
Table 2 Sociodemographic and clinical characteristics of the study group
Variables
Meningioma patients
(n = 89)
Healthy controls
(n = 89) p Value*
Characteristics
Age (years) (mean (SD)) 58.6 (12.1) 58.3 (13.3) 0.876
Sex (male) (n (%)) 23 (26) 23 (26) 1.000
Educational level (years) mean (SD) 3.8 (2.2) 3.7 (2.1) 0.859
Dexterity
Right-handed (n (%)) 83 (93) – –
Left-handed (n (%)) 2 (2) – –
Ambidextrous (n (%)) 4 (5) – –
Premorbid intelligence
Dutch Adult Reading Test (mean (SD)) 94.4 (15.7) – –
Treatment
Time since treatment (years) (mean (SD)) 3.4 (2.0) – –
Surgery only (n (%)) 67 (75) – –
Surgery and radiotherapy (n (%)) 22 (25) – –
Use of AEDs (n (%)) 23 (26) – –
Valproic acid 8 – –
Phenytoin 5 – –
Oxcarbazepine 3 – –
Levetiracetam 2 – –
Carbamazepine 2 – –
Clonazepam 1 – –
Topiramate 1 – –
Gabapentin 1 – –
Epilepsy burden{
Level 1 (n) 56 – –
Level 2 (n) 10 – –
Level 3 (n) 10 – –
Level 4 (n). 2 – –
Level 5 (n) 8 – –
Level 6 (n) 3 – –
Tumour lateralisation
Left-sided (n (%)) 37 (42) – –
Right-sided (n (%)) 25 (28) – –
Bilateral (n (%)) 27 (30) – –
Tumour localisation
Convexity (n) 45 – –
Tentorium/falx (n) 18 – –
Skull base (n) 40 – –
Orbita (n) 3 – –
Olfactorius (n) 6 – –
Tumour size and number
Volume (ml) (mean (SD)) 46.1 (51.8) – –
Area (cm2) (mean (SD)) 13.0 (1.0) – –
No of tumours (mean (SD)) 1.1 (0.6) – –
Functional/performance status
Karnofsky (mean (SD)) 81.1 (18.2) – –
Barthel (mean (SD)) 18.0 (2.8) – –
Order me 1.2 – –
*Student’s t test.
{Patient groups with higher levels representing a higher epilepsy burden; level 1, epilepsy free; level 2, epilepsy, seizure free in the
year prior to testing without AED; level 3, epilepsy, seizure free in the previous year with antiepileptic (AED) monotherapy; level 4,
epilepsy, seizure free in the previous year with AED polytherapy; level 5, epilepsy, less then six seizures in the previous year on
mono, or polytherapy; level 6, more than six seizures in the previous year and on AED mono or polytherapy.
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The Neurological Functional Scale was not indicative of
serious neurological impairment (mean 1.2 (SD 0.4)). Barthel
scores (mean 18.0 (SD 2.8)) were also not indicative of serious
limitations in patient’s ability to perform daily life activities.
The KPS scale, however, showed that the group of meningioma
patients attained suboptimal levels of physical functioning after
treatment (mean 81.1 (SD 18.2)).
Neurocognitive functioning of meningioma patients
Neurocognitive outcome of meningioma patients relative to
that of healthy controls is shown in fig 1. Neurocognitive
deficits of patients were most pronounced in executive
functioning as their mean z score was found to be 1.5 SD
below that of the healthy control group, a cut-off that is usually
held as indicative of neurocognitive impairment (p,0.001, 95%
confidence interval (CI) 21.890 to –1.364). Compared with
healthy controls, patients with meningioma also had limita-
tions in verbal memory (p,0.001, 95% CI 20.977 to 20.439),
information processing capacity (p = 0.001, 95% CI 22.034 to
20.532), psychomotor speed (p = 0.001, 95% CI 21.134 to
0.264) and working memory (p = 0.006, 95% CI 20.706 to
20.085). Attentional functioning was not found to be
significantly impaired (p = 0.448, 95% CI 20.328 to 0.319).
Neurocognitive functioning related to treatment modalities,
tumour characteristics and brain tumour related health problems
(BCM20)
Regression analyses (table 3) showed a higher epilepsy burden to
be significantly related to lower executive functioning.
Additional analyses using Student t tests revealed that patients
using AEDs (ie, groups 3, 4, 5 and 6) had significantly lower
executive functioning (p = 0.035) and psychomotor speed
(p = 0.024) than patients not using AEDs (ie, groups 1 and 2).
However, no differences in neurocognitive functioning were
found between patients with (ie, groups 5 and 6) or without (ie,
groups 1, 2, 3, and 4) epileptic seizures.
Patients who reported more communication deficits, as
evidenced by BCM20 scores, had a lower executive and
attentional functioning. Increased feelings of drowsiness were
also associated with lower information processing capacity and
psychomotor speed. Analysis using the Student’s t test showed
that patients using AEDs reported significantly more feelings of
drowsiness than patients not using AEDs (p = 0.013). However,
feelings of drowsiness could not be attributed uniquely to AED
use as AED use remained a significant predictor of executive
functioning (b=20.233) even after correcting for feelings of
drowsiness in a regression model.
Additional analysis was performed to investigate whether the
observed neurocognitive deficits among the 89 meningioma
patients were mainly due to AED use. After exclusion of
patients using AEDs, neurocognitive functioning of patients
with meningioma not using AEDs (n = 67) remained signifi-
cantly lower in all neurocognitive domains except for atten-
tional functioning relative to healthy controls (executive
functioning p,0.001; verbal memory p,0.001; information
processing p = 0.004; working memory p = 0.021; psychomotor
speed p = 0.050).
Figure 1 Mean z scores on the neurocognitive domains of patients
with meningioma relative to that of age, sex and education matched
healthy controls, represented by the ‘‘0’’ line. Lower scores indicate a
lower performance. p Values are based on t test comparisons.
Table 3 Associations between neurocognitive functioning on the one hand and tumour volume,
radiotherapy, epilepsy burden and brain tumour related health problems on the other
Neurocognitive domain
Tumour
volume Radiotherapy
Epilepsy
burden Drowsiness*
Communication
deficits*
Executive functioning b=20.076;
p = 0.579
b= 0.050;
p = 0.592
b =20.251;
p = 0.006
b=20.168;
p = 0.058
b =20.335;
p,0.001
Verbal memory b= 0.004;
p = 0.979
b=20.021;
p = 0.811
b=20.094;
p = 0.293
b= 0.034;
p = 0.746
b=20.101;
p = 0.300
Information processing b= 0.013;
p = 0.927
b=20.001;
p = 0.991
b=20.116;
p = 0.241
b =20.318;
p = 0.002
b=20.052;
p = 0.596
Psychomotor speed b=20.042;
p = 0.779
b= 0.085;
p = 0.395
b=20.163;
p = 0.105
b =20.438;
p,0.001
b=20.087;
p = 0.336
Working memory b=20.070;
p = 0.618
b=20.110;
p = 0.244
b=20.068;
p = 0.474
b=20.128;
p = 0.191
b=20.046;
p = 0.638
Attention b= 0.053;
p = 0.698
b= 0.040;
p = 0.685
b=20.120;
p = 0.221
b=20.171;
p = 0.083
b =20.203,
p = 0.037
Significant associations (p,0.05) are shown in bold type.
*BCM20 scale, brain tumour related health problems scale.
b, standardised coefficient.
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Student t tests showed tumour lateralisation and localisation
to be related to neurocognitive functioning. Patients with left-
sided meningiomas performed significantly worse on verbal
memory tasks than right-sided meningiomas (p = 0.042).
Moreover, patients with skull base meningiomas (n = 24) had
significantly lower performance in the domains of verbal
memory (p = 0.007), information processing (p = 0.033) and
psychomotor speed (p = 0.040) compared with meningiomas
located on the convexity (n = 28). In order to examine whether
dexterity affected neurocognitive outcome, we excluded left-
handed and ambidextrous patients and found that statistical
analyses yielded identical outcomes (data not shown). As
sample sizes of the different tumour locations were too small
for additional regression analysis, associations between neuro-
cognitive functioning and radiotherapy or tumour volume could
not be established.
No significant associations were found on group level
between neurocognitive functioning on the one hand and
radiotherapy and tumour volume on the other.
DISCUSSION
Thus far, only a few studies have been published on the
incidence and cause of neurocognitive deficits in patients with
meningiomas. In 2000, Tucha et al observed memory and
language impairments prior to surgery in a group of brain
tumour patients with predominantly meningiomas.25 A sub-
sequent study of Tucha et al among patients with exclusively
frontal meningiomas reported prior to and following surgery
both preoperative and postoperative serious impairment in
verbal fluency tasks which can be considered as an indication of
compromised executive functioning.26 The aforementioned
findings are in accordance with the deficits in verbal memory
and executive functioning of meningioma patients observed in
the present study.
Although patients with meningioma performed significantly
poorer than healthy controls on all neurocognitive domains, the
domain of executive functioning was most profoundly
impaired. Disturbance of executive functioning may have
considerable impact on a person’s everyday life functioning as
executive functioning is involved in neurocognitive processes
such as organising, planning and decision making.27 It is usually
considered to be linked to frontal lobe activity, although
neuroimaging studies showed executive functioning to be
dependent on other brain regions as well,28 and thereby possibly
more vulnerable to neurocognitive compromise than other
neurocognitive domains.
We found lower executive functioning to be associated with a
higher epilepsy burden, which primarily can be attributed to
AED use and not to epileptic seizures per se. A previous study
on low grade glioma patients also demonstrated AED use to
have a deleterious effect on executive functioning.12 Post hoc
analyses also showed that AED use is associated with feelings of
drowsiness. It is save to assume that the reductions in
attentiveness associated with AED use might give rise to
deficits in executive functioning of meningioma patients. The
present study only investigated the effects of older types of
AED; newer types of AED might have less detrimental effects
on neurocognitive functioning.29
Neurocognitive impairment of meningioma patients, how-
ever, cannot solely be attributed to the use of AEDs as
neurocognitive functioning among meningioma patients not
using AEDs is still compromised compared with healthy
controls.
Tumour location was found to be related to neurocognitive
functioning. Verbal memory deficits in left-sided meningioma
patients are to be expected as the left hemisphere is dominant
for language in the majority of people. Dexterity is unlikely to
be a confounding variable of neurocognitive functioning as
exclusion of left-handed and ambidextrous patients yielded the
same neurocognitive outcomes. The above mentioned finding is
in accordance with the more severe neurocognitive disability of
patients with low grade glioma in the dominant hemisphere
compared with non-dominant low grade gliomas.30 Patients
with skull base meningiomas were found to have worse
neurocognitive functioning than those with convexity menin-
giomas, especially concerning more basic neurocognitive func-
tions such as information processing speed and psychomotor
speed. Skull base meningiomas may be more prone to
neurocognitive damage because of the inherent more difficult
surgery.31
No statistically significant associations were found between
adjuvant radiotherapy and neurocognitive functioning. In a
recently published study on a subset of the present study, in
which surgically treated patients were individually matched to
patients who underwent adjuvant radiotherapy after surgery,
we also found no indication that radiotherapy is detrimental to
an already impaired neurocognitive functioning.32
Evidently, this study has its limitations. Since a pretreatment
assessment is lacking, a comprehensive differentiation between
tumour and treatment related factors (ie, effects of surgery)
cannot be made. A prospective study including pre-surgery
assessment of neurocognitive function is planned to start
shortly.
In conclusion, this study demonstrates that patients with
meningioma have extensive long term neurocognitive deficits
following treatment with or without adjuvant radiotherapy.
Our results indicate that the influence of radiotherapy on
neurocognition is negligible whereas the use of AEDs negatively
affects neurocognitive functioning.
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